Kymera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Kymera Therapeutics's earnings have been declining at an average annual rate of -28%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 27% per year.
Key information
-28.0%
Earnings growth rate
61.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 27.0% |
| Return on equity | -18.8% |
| Net Margin | -191.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Kymera: Protein Degradation Could Drive Dupixent-Like Value
Dec 07Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Revenue & Expenses Breakdown
How Kymera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 88 | -167 | 61 | 0 |
| 30 Jun 24 | 89 | -158 | 60 | 0 |
| 31 Mar 24 | 79 | -155 | 57 | 0 |
| 31 Dec 23 | 79 | -147 | 55 | 0 |
| 30 Sep 23 | 47 | -167 | 52 | 0 |
| 30 Jun 23 | 52 | -158 | 49 | 0 |
| 31 Mar 23 | 47 | -159 | 46 | 0 |
| 31 Dec 22 | 47 | -155 | 44 | 0 |
| 30 Sep 22 | 46 | -154 | 44 | 0 |
| 30 Jun 22 | 57 | -139 | 44 | 0 |
| 31 Mar 22 | 64 | -124 | 41 | 0 |
| 31 Dec 21 | 73 | -100 | 36 | 0 |
| 30 Sep 21 | 70 | -79 | 30 | 0 |
| 30 Jun 21 | 65 | -58 | 26 | 0 |
| 31 Mar 21 | 49 | -48 | 22 | 0 |
| 31 Dec 20 | 34 | -55 | 18 | 0 |
| 30 Sep 20 | 23 | -53 | 16 | 0 |
| 30 Jun 20 | 9 | -57 | 10 | 0 |
| 31 Mar 20 | 6 | -52 | 9 | 0 |
| 31 Dec 19 | 3 | -41 | 8 | 0 |
Quality Earnings: KYMR is currently unprofitable.
Growing Profit Margin: KYMR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KYMR is unprofitable, and losses have increased over the past 5 years at a rate of 28% per year.
Accelerating Growth: Unable to compare KYMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KYMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KYMR has a negative Return on Equity (-18.76%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 18:43 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Etzer Darout | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |